Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Oncotarget
; 13: 1314-1321, 2022 12 06.
Article
in En
| MEDLINE
| ID: mdl-36473155
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
/
Qualitative_research
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Oncotarget
Year:
2022
Type:
Article
Affiliation country:
United States